Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Provides osmotic gradient for peritoneal dialysis; glucose and icodextrin facilitate ultrafiltration and removal of waste products across the peritoneal membrane.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
2 L intraperitoneally via an indwelling peritoneal catheter, dwell time 4-6 hours, 4 exchanges per day
None Documented
None Documented
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Not applicable as a traditional half-life; removal is dependent on peritoneal dialysis dwell time and membrane transport characteristics. Effective clearance half-life during dialysis is approximately 2-4 hours depending on exchange schedule.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Primarily removed via peritoneal dialysis; minimal renal excretion (less than 5% unchanged). Dextrose is metabolized to CO2 and water. Biliary/fecal excretion negligible.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution